<<< BACK

VIMRX ANNOUNCES LAUNCH OF INTERNET SITE
WWW.VIMRX.COM Offers Updates on VIMRX Research
and Share Price

Wilmington, DE, January 14, 1997 — VIMRX Pharmaceuticals, Inc. (Nasdaq: VMRX), a development-stage biotech company that specializes in therapies to fight viral and retroviral diseases, as well as cancer, today announced that it has created its own Internet site: www.vimrx.com.

Investors, researchers, medical practitioners and other interested parties can obtain the latest information on VIMRx’s current research projects and share price, as well as details on the Company’s mission, management team and major transactions. Scrolling text on the site’s home page highlights recent news on the Company, while another area of the site includes summaries and full text of all VIMRX press releases since 1995.

"Besides our shareholders, a large and growing number of people interested in medical advances and investment opportunities closely follow developments in the biotech sector," stated Richard L. Dunning, VIMRx’s President and CEO. "We are happy to offer all these individuals the added convenience of this Internet site, as a means to keep current with events in VIMRx’s fast-paced field."

Going forward, the VIMRX Internet site will include news releases and other information on Innovir Laboratories, Inc. (NASDAQ SmallCap: INVR), in which VIMRX gained 68% ownership on January 2, 1997. VIMRX and Innovir have both been leaders in Oligozyme technology — which, in contrast to conventional medicine, may allow the treatment and prevention of diseases by blocking the transmission of illness-causing information that is encoded in specific genes. All of VIMRx’s Oligozyme research has been consolidated under the Innovir name.

VIMRx’s Internet site is interactive, allowing readers to request more information or offer comments via Internet e-mail.

VIMRx, based in Wilmington, DE, is currently developing two technology platforms: chemically synthesized hypericin, VIMRxyn®, and through its majority-owned affiliate, Innovir Laboratories, catalytically active Oligozymes. VIMRxyn® is currently in clinical development for the treatment of HIV, brain cancer and hepatitis C, and is in pre-clinical development for the sterilization of blood. Innovir’s Oligozyme technology seeks to control disease-triggering flaws in individuals’ genetic chemistry. In addition to its potential use as a therapeutic in attacking diseases at the genetic level, the Oligozyme technology is being developed as a pharmaceutical research tool, to aid in drug target identification and validation. VIMRX also intends to be active in identifying and acquiring additional technologies and products.

#  #  #

Copyright © 1994-2001 meister.NET. All rights reserved.
Legal Notices & Disclaimers

meister.NET

media exposure

contact